The stock has demonstrated consistent upward movement, registering gains for five consecutive days and delivering a cumulative return of 4.26% during this period. This performance notably outpaced its sector by 1.01% on the day of the new high. Trading above all major moving averages — including the 5-day, 20-day, 50-day, 100-day, and 200-day averages — Laurus Labs exhibits a robust technical position that reflects positive investor sentiment and market dynamics.
Over the past year, Laurus Labs has delivered a remarkable return of 112.18%, significantly outperforming the Sensex, which recorded a 9.46% return in the same timeframe. The stock’s 52-week low was Rs.475.45, highlighting the extent of its price appreciation over the last twelve months.
Handpicked from 50, scrutinized by experts – Our recent selection, this mid-cap from Pharmaceuticals & Biotechnology, is already delivering results. Don't miss next month's pick!
- Expert-scrutinized selection
- Already delivering results
- Monthly focused approach
Financially, Laurus Labs has shown strong metrics that underpin its market performance. The company reported a net profit growth of 993.4% in its September 2025 quarter, marking a continuation of positive results for four consecutive quarters. The Profit Before Tax (PBT) excluding other income stood at Rs.242.77 crores, reflecting a growth of 1233.17%, while the Profit After Tax (PAT) was Rs.194.97 crores, growing by 882.7%. Operating profit to interest ratio reached a high of 10.08 times, indicating efficient management of operational earnings relative to interest expenses.
Management efficiency is further highlighted by a Return on Capital Employed (ROCE) of 16.75%, a figure that supports the company’s ability to generate returns from its capital base. Institutional holdings account for 37.63% of the stock, suggesting a significant stake by investors with substantial analytical resources.
Despite the strong recent performance, the company’s operating profit has grown at an annual rate of 5.37% over the past five years, indicating a more moderate long-term growth trajectory. The stock’s valuation metrics show an Enterprise Value to Capital Employed ratio of 8.2, which is considered high, reflecting a premium valuation relative to capital employed. However, the stock currently trades at a discount compared to its peers’ average historical valuations.
In the broader market context, the Sensex opened 91.42 points higher but later declined by 393.30 points, trading at 84,649.07, down 0.36%. The index remains close to its 52-week high of 85,290.06, just 0.76% away, and is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, signalling a generally bullish market environment.
Want to dive deeper on Laurus Labs ? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- Real-time research report
- Complete fundamental analysis
- Peer comparison included
Over the last three years, Laurus Labs has outperformed the BSE500 index across multiple timeframes, including one year and three months, reinforcing its position as a market-beating stock within the Pharmaceuticals & Biotechnology sector. The company’s PEG ratio stands at 0.2, reflecting the relationship between its price-to-earnings ratio and earnings growth rate over the past year, where profits have risen by 421.7%.
In summary, Laurus Labs’ achievement of a new 52-week high at Rs.1033.55 is supported by strong financial results, sustained price momentum, and favourable technical indicators. The stock’s performance contrasts with the broader market’s modest fluctuations, highlighting its relative strength within the sector and market.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
